Checkpoint Therapeutics Inc (CKPT) concluded trading on Wednesday at a closing price of $4.23, with 12.19 million shares of worth about $51.56 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 21.90% during that period and on Wednesday the price saw a gain of about 0.95%. Currently the company’s common shares owned by public are about 83.06M shares, out of which, 74.14M shares are available for trading.
Stock saw a price change of 1.68% in past 5 days and over the past one month there was a price change of 2.92%. Year-to-date (YTD), CKPT shares are showing a performance of 32.19% which increased to 129.89% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $1.75 but also hit the highest price of $4.50 during that period. The average intraday trading volume for Checkpoint Therapeutics Inc shares is 2.82 million. The stock is currently trading 1.75% above its 20-day simple moving average (SMA20), while that difference is up 3.53% for SMA50 and it goes to 27.76% higher than SMA200.
Checkpoint Therapeutics Inc (NASDAQ: CKPT) currently have 83.06M outstanding shares and institutions hold larger chunk of about 36.86% of that.
The stock has a current market capitalization of $368.09M and its 3Y-monthly beta is at 1.13. It has posted earnings per share of -$1.13 in the same period. It has Quick Ratio of 1.91 while making debt-to-equity ratio of 0.00. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for CKPT, volatility over the week remained 0.49% while standing at 0.34% over the month.
Analysts are in expectations that Checkpoint Therapeutics Inc (CKPT) stock would likely to be making an EPS of -0.02 in the current quarter, while forecast for next quarter EPS is 0.17 and it is 1.13 for next year. For the current quarter EPS, analysts have given the company a lowest target -0.02 which is -0.02 at the higher side of the target for the same. Stock’s fiscal year EPS is expected to rise by 80.63% while it is estimated to increase by 510.91% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by D. Boral Capital on January 13, 2025 offering a Buy rating for the stock and assigned a target price of $9 to it. Coverage by B. Riley Securities stated Checkpoint Therapeutics Inc (CKPT) stock as a Buy in their note to investors on July 14, 2022, suggesting a price target of $7 for the stock. On June 09, 2021, B. Riley Securities Initiated their recommendations, while on January 20, 2021, Cantor Fitzgerald Initiated their ratings for the stock with a price target of $16. Stock get a Buy rating from Lake Street on May 29, 2019.
